Allianz Asset Management GmbH Raises Stock Holdings in Adaptive Biotechnologies Corporation $ADPT

Allianz Asset Management GmbH boosted its position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 305.8% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 321,774 shares of the company’s stock after acquiring an additional 242,474 shares during the quarter. Allianz Asset Management GmbH owned about 0.21% of Adaptive Biotechnologies worth $4,814,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. First Trust Advisors LP increased its holdings in shares of Adaptive Biotechnologies by 4,802.2% during the 2nd quarter. First Trust Advisors LP now owns 741,306 shares of the company’s stock valued at $8,636,000 after purchasing an additional 726,184 shares in the last quarter. Peregrine Capital Management LLC purchased a new stake in Adaptive Biotechnologies during the second quarter worth $8,187,000. Hillsdale Investment Management Inc. acquired a new stake in Adaptive Biotechnologies during the second quarter valued at $6,618,000. Cubist Systematic Strategies LLC purchased a new position in Adaptive Biotechnologies in the second quarter valued at $5,346,000. Finally, Geode Capital Management LLC raised its position in shares of Adaptive Biotechnologies by 15.6% in the second quarter. Geode Capital Management LLC now owns 3,215,171 shares of the company’s stock worth $37,461,000 after acquiring an additional 434,347 shares during the period. 99.17% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, CEO Chad M. Robins sold 124,998 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $18.44, for a total value of $2,304,963.12. Following the sale, the chief executive officer owned 2,459,245 shares of the company’s stock, valued at $45,348,477.80. The trade was a 4.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Kyle Piskel sold 2,145 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $18.46, for a total transaction of $39,596.70. Following the completion of the transaction, the chief financial officer directly owned 216,637 shares of the company’s stock, valued at approximately $3,999,119.02. The trade was a 0.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 1,513,196 shares of company stock valued at $26,291,033 over the last 90 days. Insiders own 6.40% of the company’s stock.

Adaptive Biotechnologies Stock Down 1.4%

Shares of ADPT opened at $15.64 on Wednesday. Adaptive Biotechnologies Corporation has a 52-week low of $6.26 and a 52-week high of $20.76. The stock has a market cap of $2.39 billion, a PE ratio of -39.10 and a beta of 2.18. The firm’s fifty day moving average is $16.91 and its two-hundred day moving average is $15.33.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. The company had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm’s revenue for the quarter was up 51.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.23) earnings per share. As a group, research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Wall Street Analyst Weigh In

ADPT has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. BTIG Research upped their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday. Morgan Stanley started coverage on shares of Adaptive Biotechnologies in a research note on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price target on the stock. TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday. Finally, Piper Sandler set a $21.00 price objective on shares of Adaptive Biotechnologies in a research report on Friday. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $17.56.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.